Context Therapeutics Doses First Patient in CT-202 Phase 1
PHILADELPHIA — September 9, 2026 Context Therapeutics Inc. announced that the first patient has been dosed in the Phase...
Nectin-4
Advertisement
Corbus Moves CRB-701 Toward FDA Registration
NORWOOD, Mass., July 28, 2026 Corbus Pharmaceuticals Holdings, Inc. has received U.S. Food and Drug Administration (FDA) clearance to...
Innate Pharma Reaches Phase 1 Enrollment Milestone for IPH4502
Marseille, France | July 21, 2026 Innate Pharma SA has announced the completion of enrollment in the dose-escalation portion...
Akeso Starts Phase II Trial of AK146D1 for Advanced NSCLC
HONG KONG, July 20, 2026 Akeso, Inc. has announced a significant milestone in its oncology pipeline with the first...
Genentech FDA Filing Advances Lunsumio-Polivy in LBCL
SOUTH SAN FRANCISCO, Calif., June 17, 2026 Genentech, a member of the Roche Group, has reached a significant regulatory...
Advertisements
Mabwell Showcases Strong 9MW2821 Cervical Cancer Data
COPENHAGEN, Denmark, June 18, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, has unveiled encouraging...
Mabwell 9MW2821 Advances to Phase III in TNBC Trial
SHANGHAI, April 23, 2026 Mabwell has announced the initiation of a Phase III clinical trial for its proprietary Nectin-4-targeting...
Rondo Therapeutics Begins Phase I Trial of RNDO-564 in Advanced Tumors
Dateline – San Francisco, CA – December 2025: Rondo Therapeutics has dosed the first patient in its Phase I...
Advertisement
